
Tom T Shimabukuro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3045054/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA - Journal of the American Medical Association, 2021, 325, 2448.	3.8	463
2	Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA - Journal of the American Medical Association, 2022, 327, 331.	3.8	434
3	Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021. Morbidity and Mortality Weekly Report, 2021, 70, 977-982.	9.0	431
4	Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine, 2015, 33, 4398-4405.	1.7	416
5	Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. JAMA - Journal of the American Medical Association, 2021, 325, 1101.	3.8	335
6	First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 283-288.	9.0	314
7	Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA - Journal of the American Medical Association, 2021, 325, 780.	3.8	247
2	Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson) Tj ETQq0	0	
8	Committee on Immunization Practices — United States, July 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1094-1099.	9.0	169
9	Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021. Morbidity and Mortality Weekly Report, 2021, 70, 680-684.	9.0	152
10	COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1755-1760.	9.0	126
11	COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1053-1058.	9.0	123
12	Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet Infectious Diseases, The, 2022, 22, 802-812.	4.6	102
13	Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021. Annals of Internal Medicine, 2022, 175, 513-522.	2.0	93
14	Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021. Morbidity and Mortality Weekly Report, 2022, 71, 90-95.	9.0	82
15	The MMR Vaccine and Autism. Annual Review of Virology, 2019, 6, 585-600.	3.0	67
16	U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. Vaccine, 2021, 39, 3666-3677.	1.7	61
17	Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022. Morbidity and Mortality Weekly Report, 2022, 71, 249-254.	9.0	59
18	Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021. Morbidity and Mortality Weekly Report, 2021, 70, 685-688.	9.0	58

Том Т Ѕнімавикиго

#	Article	IF	CITATIONS
19	Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009–2015. Vaccine, 2018, 36, 1781-1788.	1.7	51
20	Shoulder Injury Related to Vaccine Administration (SIRVA): Petitioner claims to the National Vaccine Injury Compensation Program, 2010–2016. Vaccine, 2020, 38, 1076-1083.	1.7	50
21	Reports of atypical shoulder pain and dysfunction following inactivated influenza vaccine, Vaccine Adverse Event Reporting System (VAERS), 2010–2017. Vaccine, 2020, 38, 1137-1143.	1.7	41
22	Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012–13, 2013–14, and 2014–15. Vaccine, 2019, 37, 6673-6681.	1.7	39
23	Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics, 2019, 144, .	1.0	39
24	Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021. American Journal of Transplantation, 2021, 21, 1326-1331.	2.6	39
25	Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020. American Journal of Transplantation, 2021, 21, 1332-1337.	2.6	37
26	Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018. Morbidity and Mortality Weekly Report, 2019, 68, 91-94.	9.0	37
27	Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years. Pediatrics, 2022, 150, .	1.0	37
28	Deaths Reported to the Vaccine Adverse Event Reporting System, United States, 1997–2013. Clinical Infectious Diseases, 2015, 61, 980-987.	2.9	35
29	Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022. Morbidity and Mortality Weekly Report, 2022, 71, 347-351.	9.0	33
30	Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System. Journal of Adolescent Health, 2017, 61, 577-582.	1.2	28
31	Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008–2012. Vaccine, 2018, 36, 553-558.	1.7	28
32	Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006–2015. Human Vaccines and Immunotherapeutics, 2018, 14, 1963-1969.	1.4	24
33	Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax®) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013–2015. Vaccine, 2015, 33, 6684-6688.	1.7	19
34	Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009–2017. British Journal of Clinical Pharmacology, 2018, 84, 2928-2932.	1.1	18
35	Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990–2013. Vaccine, 2016, 34, 2841-2846.	1.7	17
36	<i>Notes from the Field:</i> Vaccine Administration Errors Involving Recombinant Zoster Vaccine — United States, 2017–2018. Morbidity and Mortality Weekly Report, 2018, 67, 585-586.	9.0	11

#	Article	IF	CITATIONS
37	Expected Rates of Select Adverse Events After Immunization for Coronavirus Disease 2019 Vaccine Safety Monitoring. Journal of Infectious Diseases, 2022, 225, 1569-1574.	1.9	10
38	Cognitive testing to evaluate revisions to the Vaccine Adverse Event Reporting System (VAERS) reporting form. Vaccine, 2017, 35, 2295-2297.	1.7	2
39	Unintentional administration of insulin instead of influenza vaccine: a case study and review of reports to US vaccine and drug safety monitoring systems. Drugs and Therapy Perspectives, 2016, 32, 439-446.	0.3	1
40	Vaccine Safety. , 2019, , 1-24.		0

4